Selective radioprotection of normal tissues by Bowman-Birk proteinase inhibitor (BBI) in mice

Strahlentherapie und Onkologie

Volumn 181, Issue 3, 2005, Pages 191-196

  Dittmann, Klaus ^a   Toulany, Mahmoud ^a   Classen, Johannes ^a   Heinrich, Vanessa ^a   Milas, Luka ^b   Rodemann, H Peter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Leg contracture; Normal tissue radioprotector; TP53; Tumor growth delay

Indexed keywords

BOWMAN BIRK INHIBITOR; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRACTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SELECTIVITY; EXPERIMENTAL MODEL; FEMALE; FIBROSARCOMA; FIBROSIS; GENE MUTATION; LEG; MALE; MOUSE; NONHUMAN; PREMEDICATION; RADIATION INJURY; RADIATION PROTECTION; STUDENT T TEST; TISSUE SPECIFICITY; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CELL DIVISION; FEMALE; HINDLIMB; MALE; MICE; MICE, INBRED C3H; MODELS, ANIMAL; MUSCLE CONTRACTION; NEOPLASMS, EXPERIMENTAL; RADIATION PROTECTION; RADIOTHERAPY; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN;

EID: 17044370493     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-005-1358-y     Document Type: Article

References (32)

1. Armstrong WB, Kennedy AR, Wan XS, et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000;6:4684-91.
2. Billings PC, Newberne PM, Kennedy AR. Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis 1990;11:1083-6.
3. Bohuslavizki KH, Klutmann S, Brenner W, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. Strahlenther Onkol 1999;175:Suppl 4:6-12.
4. Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol 1999;26:72-81.
5. Delanian S. Striking regression of radiation-induced fibrosis by a combination of pentoxifylline and tocopherol. Br J Radiol 1998;71:892-4.
6. Delanian S, Porcher R, Balla-Mekias S, et al. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003;21:2545-50.
7. Dittmann K, Loffler H, Bamberg M, et al. Bowman-Birk proteinase inhibitor (BBI) modulates radiosensitivity and radiation-induced differentiation of human fibroblasts in culture. Radiother Oncol 1995;34:137-43.
8. Dittmann K, Virsik-Kopp P, Mayer C, et al. Bowman-Birk protease inhibitor activates DNA-dependent protein kinase and reduces formation of radiation-induced dicentric chromosomes. Int J Radiat Biol 2003;79:801-8.
9. Dittmann KH, Gueven N, Mayer C, et al. The presence of wild-type TP53 is necessary for the radioprotective effect of the Bowman-Birk proteinase inhibitor in normal fibroblasts. Radiat Res 1998;150:648-55.
10. Dittmann KH, Gueven N, Mayer C, et al. The radioprotective effect of BBI is associated with the activation of DNA repair-relevant genes. Int J Radiat Biol 1998;74:225-30.
11. Duchstein S, Gademann G, Peters B. [Early and late effects of local high dose radiotherapy of the brain on memory and attention.] Strahlenther Onkol 2003;179:441-51.
12. Herskind C, Bamberg M, Rodemann HP. The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol 1998;174:Suppl 3:12-5.
13. Herskind C, Johansen J, Bentzen SM, et al. Fibroblast differentiation in subcutaneous fibrosis after postmastectomy radiotherapy. Acta Oncol 2000;39:383-8.
14. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991;253:49-53.
15. Hospers GA, Eisenhauer EA, de Vries EG. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer 1999;80:629-38.
16. Kennedy AR. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr 1998;68:1406S-12S.
17. Kennedy AR, Billings PC, Maki PA, et al. Effects of various preparations of dietary protease inhibitors on oral carcinogenesis in hamsters induced by DMBA. Nutr Cancer 1993;19:191-200.
18. Kennedy AR, Szuhaj BF, Newberne PM, et al. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer 1993;19:281-302.
19. Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003;22:5897-906.
20. Kouvaris J, Kouloulias V, Malas E, et al. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy. Strahlenther Onkol 2003;179:167-74.
21. Kuechler A, Dreidax M, Pigorsch SU, et al. Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH. Strahlenther Onkol 2003;179:493-8.
22. Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector [Comment]? Radiother Oncol 2000;57:113-8.
23. Milas L, Hunter N, Ito H, et al. In vivo radioprotective activities of diethyldithiocarbamate (DDC). Int J Radiat Oncol Biol Phys 1984;10:2335-43.
24. Milas L, Hunter N, Reid BO, et al. Protective effects of S-2-(3-aminopropyl amino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice. Cancer Res 1982;42:1888-97.
25. Rodemann HP, Binder A, Burger A, et al. The underlying cellular mechanism of fibrosis. Kidney Int Suppl 1996;54:S32-6.
26. Rodemann HP, Peterson HP, Schwenke K, et al. Terminal differentiation of human fibroblasts is induced by radiation. Scanning Microsc 1991;5:1135-42, discussion 42-3.
27. Schimming R, Mason KA, Hunter N, et al. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 1999;43:165-72.
28. Stone HB. Leg contracture in mice: an assay of normal tissue response. Int J Radiat Oncol Biol Phys 1984;10:1053-61.
29. Stone HB, Milas L. Enhancement of radiation-induced normal tissue damage by a fibrosarcoma. Int J Radiat Oncol Biol Phys 1987;13:1721-4.
30. Vacha P, Fehlauer F, Mahlmann B, et al. Randomized phase III trial of post-operative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 2003;179:385-9.
31. Wasserman TH. Radiotherapeutic studies with amifostine (Ethyol). Semin Oncol 1994;21:21-5.
32. Yavelow J, Caggana M, Beck KA. Proteases occurring in the cell membrane: a possible cell receptor for the Bowman-Birk type of protease inhibitors. Cancer Res 1987;47:1598-601.